These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37062440)

  • 1. Tumor necrosis factor-α inhibitor-related autoimmune disorders.
    De Stefano L; Pallavicini FB; Mauric E; Piccin V; Vismara EM; Montecucco C; Bugatti S
    Autoimmun Rev; 2023 Jul; 22(7):103332. PubMed ID: 37062440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics in Inflammatory Immune-mediated Systemic Diseases.
    Moroncini G; Calogera G; Benfaremo D; Gabrielli A
    Curr Pharm Biotechnol; 2017; 18(12):1008-1016. PubMed ID: 29278213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: From conventional to cutting edge in biologics and RNA- based nanomedicines.
    Andretto V; Dusi S; Zilio S; Repellin M; Kryza D; Ugel S; Lollo G
    Adv Drug Deliv Rev; 2023 Oct; 201():115080. PubMed ID: 37660747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.
    Jang DI; Lee AH; Shin HY; Song HR; Park JH; Kang TB; Lee SR; Yang SH
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.
    Yabe M; Medeiros LJ; Daneshbod Y; Davanlou M; Bueso-Ramos CE; Moran EJ; Young KH; Miranda RN
    Ann Diagn Pathol; 2017 Feb; 26():16-22. PubMed ID: 28038706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).
    Pérez-De-Lis M; Retamozo S; Flores-Chávez A; Kostov B; Perez-Alvarez R; Brito-Zerón P; Ramos-Casals M
    Expert Opin Drug Saf; 2017 Nov; 16(11):1255-1271. PubMed ID: 28854831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update upon efficacy and safety of TNF-α inhibitors.
    Murdaca G; Colombo BM; Cagnati P; Gulli R; Spanò F; Puppo F
    Expert Opin Drug Saf; 2012 Jan; 11(1):1-5. PubMed ID: 22010813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases.
    Willrich MA; Murray DL; Snyder MR
    Transl Res; 2015 Feb; 165(2):270-82. PubMed ID: 25305470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.
    Lopetuso LR; Cuomo C; Mignini I; Gasbarrini A; Papa A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor necrosis factor blocking agents: a review. Part I: Clinical efficacy evaluation].
    Rodríguez Moreno C; López Vázquez P; Durán Parrondo C; Tato Herrero F; Lado Lado F
    An Med Interna; 2006 Jan; 23(1):37-45. PubMed ID: 16542122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight of Engineered Nano-based Biologics Approaches used to Combat Autoimmune Disease using TNF-α & IL Inhibitors.
    Patil D; Ajazuddin ; Bhattacharya S
    Curr Top Med Chem; 2023; 23(19):1793-1806. PubMed ID: 36999698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications.
    Murdaca G; Colombo BM; Puppo F
    Drugs Today (Barc); 2011 Apr; 47(4):277-88. PubMed ID: 21573251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.
    Blandizzi C; Gionchetti P; Armuzzi A; Caporali R; Chimenti S; Cimaz R; Cimino L; Lapadula G; Lionetti P; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Girolomoni G
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):1-10. PubMed ID: 24774503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F; Chiappelli M; Ianni M; Porcellini E
    Int J Immunopathol Pharmacol; 2009; 22(3):567-72. PubMed ID: 19822073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential target of infliximab in autoimmune and inflammatory diseases.
    Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.
    Alijotas-Reig J; Esteve-Valverde E; Ferrer-Oliveras R; Llurba E; Gris JM
    Clin Rev Allergy Immunol; 2017 Aug; 53(1):40-53. PubMed ID: 28054230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    Feldmann M; Maini RN
    Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapies: what and when?
    Johnston SL
    J Clin Pathol; 2007 Jan; 60(1):8-17. PubMed ID: 17213345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Shivaji UN; Sharratt CL; Thomas T; Smith SCL; Iacucci M; Moran GW; Ghosh S; Bhala N
    Aliment Pharmacol Ther; 2019 Mar; 49(6):664-680. PubMed ID: 30735257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.